Evidence map›Paper›PMID 34833859›Full record

ArticleMolecules (Basel, Switzerland)2021

Martina Vermathen, Hendrik von Tengg-Kobligk, Martin Nils Hungerbühler, Peter Vermathen, Nico Ruprecht

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Use of Nuclear Magnetic Resonance (NMR) to Study Cancer Metabolism.Advances in experimental medicine and biology · 2026
    Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Metabolomics in Cell Biology.Handbook of experimental pharmacology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Martina VermathenDepartment of Chemistry, Biochemistry and Pharmaceutical Sciences, University of Bern, 3012 Bern, Switzerland.
Hendrik von Tengg-KobligkDepartment of Diagnostic, Interventional and Pediatric Radiology, Bern University Hospital, University of Bern, 3010 Bern, Switzerland.ORCID 0000-0003-3207-3223
Martin Nils HungerbühlerDepartment of Diagnostic, Interventional and Pediatric Radiology, Bern University Hospital, University of Bern, 3010 Bern, Switzerland.ORCID 0000-0001-8316-3072
Peter VermathenDepartment of BioMedical Research, University of Bern, 3008 Bern, Switzerland.ORCID 0000-0001-8649-1098
Nico RuprechtDepartment of Diagnostic, Interventional and Pediatric Radiology, Bern University Hospital, University of Bern, 3010 Bern, Switzerland.ORCID 0000-0002-3940-9546
University of Bern · CH

Funding

Swiss National Science Foundation 206021-128736
6 · The paper itself

Abstract

Cisplatin (cisPt) is an important drug that is used against various cancers, including advanced lung cancer. However, drug resistance is still a major ongoing problem and its investigation is of paramount interest. Here, a high-resolution magic angle spinning (HR-MAS) NMR study is presented deciphering the metabolic profile of non-small cell lung cancer (NSCLC) cells and metabolic adaptations at different levels of induced cisPt-resistance, as well as in their de-induced counterparts (cells cultivated in absence of cisPt). In total, fifty-three metabolites were identified and quantified in the

Indexed as

MetabolomeNuclear Magnetic Resonance, BiomolecularCarcinoma, Non-Small-Cell LungCell Line, TumorCisplatinDrug Resistance, NeoplasmHumansLung NeoplasmsCisplatincisplatincisPt resistanceHR-MAS NMRmetabolomicsnon-small cell lung cancerNSCLC

Identifiers

PMID34833859
PMCPMC8625954
OpenAlexW3213523205

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.